TY  - JOUR
AU  - Kleineberg, Nina N.
AU  - Knauss, Samuel
AU  - Gülke, Eileen
AU  - Pinnschmidt, Hans O.
AU  - Jakob, Carolin E. M.
AU  - Lingor, Paul
AU  - Hellwig, Kerstin
AU  - Berthele, Achim
AU  - Höglinger, Günter
AU  - Fink, Gereon R.
AU  - Endres, Matthias
AU  - Gerloff, Christian
AU  - Klein, Christine
AU  - Stecher, Melanie
AU  - Classen, Annika Y.
AU  - Rieg, Siegbert
AU  - Borgmann, Stefan
AU  - Hanses, Frank
AU  - Rüthrich, Maria M.
AU  - Hower, Martin
AU  - Tometten, Lukas
AU  - Haselberger, Martina
AU  - Piepel, Christiane
AU  - Merle, Uta
AU  - Dolff, Sebastian
AU  - Degenhardt, Christian
AU  - Jensen, Björn-Erik O.
AU  - Vehreschild, Maria J. G. T.
AU  - Erber, Johanna
AU  - Franke, Christiana
AU  - Warnke, Clemens
TI  - Neurological symptoms and complications in predominantly hospitalized COVID‐19 patients: Results of the European multinational Lean European Open Survey on SARS‐Infected Patients (LEOSS)
JO  - European journal of neurology
VL  - 28
IS  - 12
SN  - 1351-5101
CY  - Oxford
PB  - Blackwell Science
M1  - FZJ-2021-03869
SP  - 3925-3937
PY  - 2021
AB  - Background and purposeDuring acute coronavirus disease 2019 (COVID-19) infection, neurological signs, symptoms and complications occur. We aimed to assess their clinical relevance by evaluating real-world data from a multinational registry.MethodsWe analyzed COVID-19 patients from 127 centers, diagnosed between January 2020 and February 2021, and registered in the European multinational LEOSS (Lean European Open Survey on SARS-Infected Patients) registry. The effects of prior neurological diseases and the effect of neurological symptoms on outcome were studied using multivariate logistic regression.ResultsA total of 6537 COVID-19 patients (97.7% PCR-confirmed) were analyzed, of whom 92.1% were hospitalized and 14.7% died. Commonly, excessive tiredness (28.0%), headache (18.5%), nausea/emesis (16.6%), muscular weakness (17.0%), impaired sense of smell (9.0%) and taste (12.8%), and delirium (6.7%) were reported. In patients with a complicated or critical disease course (53%) the most frequent neurological complications were ischemic stroke (1.0%) and intracerebral bleeding (ICB; 2.2%). ICB peaked in the critical disease phase (5%) and was associated with the administration of anticoagulation and extracorporeal membrane oxygenation (ECMO). Excessive tiredness (odds ratio [OR] 1.42, 95% confidence interval [CI] 1.20–1.68) and prior neurodegenerative diseases (OR 1.32, 95% CI 1.07–1.63) were associated with an increased risk of an unfavorable outcome. Prior cerebrovascular and neuroimmunological diseases were not associated with an unfavorable short-term outcome of COVID-19.ConclusionOur data on mostly hospitalized COVID-19 patients show that excessive tiredness or prior neurodegenerative disease at first presentation increase the risk of an unfavorable short-term outcome. ICB in critical COVID-19 was associated with therapeutic interventions, such as anticoagulation and ECMO, and thus may be an indirect complication of a life-threatening systemic viral infection.
LB  - PUB:(DE-HGF)16
C6  - 34411383
UR  - <Go to ISI:>//WOS:000692461300001
DO  - DOI:10.1111/ene.15072
UR  - https://juser.fz-juelich.de/record/901854
ER  -